An ‘evolving' pattern in serum M-protein independently predicted for progression to MM in a single-center cohort, with a 2-year progression risk of 45%,13 and a similar risk was observed in a SWOG study among patients in whom there was a change in M-protein from <3 to ⩾3 g/dl over a period of 4 months.14 However, post hoc analysis from the observation arm of the Spanish trial suggested that progression risk was comparable between patients with and without evolving changes in M-protein.15 The gene discussed is MYOM2; the disease is Miyoshi myopathy.